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ve equal contributiAbstract Glycolysis, a simple pathway of glucose metabolism, critically regulates insulin secretion and
metabolic functions of various cells. Depending on cell types, rates of glycolysis are determined at
various steps of glycolysis that are subjected to the control of key metabolic and regulatory enzyme(s),
which include glucokinase, 6-phosphofructo-1-kinase, and 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase. These enzymes are regulated by both nutritional and hormonal signals at the levels
of transcription, translation, and post-translational modiﬁcations. In hepatocytes, glycolysis is involved
in the control of hepatic glucose production. The latter, when excessive, contributes to hyperglycemia in
diabetes. In pancreatic b cells, glycolysis couples glucose-stimulated insulin secretion. Absolute or
relatively low levels of circulating insulin causes hyperglycemia. In adipocytes, glycolysis generates
metabolites for lipogenesis and channels fatty acids from excessive oxidation to triglyceride synthesis,
thereby reducing oxidative stress. With increased proinﬂammatory status, adipocytes produce pro-
hyperglycemic factors and bring about hyperglycemia and insulin resistance. In hypothalamic neurons,
glycolysis conveys nutrient sensing that is related to feeding control. Dysregulation of glycolysis occurs
in conditions of insulin deﬁciency or resistance, and is attributable to inappropriate amount and/oredica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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Glycolysis in the control of blood glucose homeostasis 359activities of metabolic and regulatory enzymes of glycolysis. Targeting key metabolic and regulatory
enzymes to enhance glycolysis may offer viable approaches for treatment of diabetes.
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the generation of pyruvate/lactate from glucose. Depending on
cell types in which glycolysis occurs, glucose uptake is mediated1. Introduction
Glycolysis is the pathway of breakdown of glucose into
pyruvate/lactate following glucose uptake by cells and glucose
phosphorylation. Glycolysis also provides the substrates for
energy production via the formation of ATP as well as
substrates for storage pathways of glycogenesis and lipogen-
esis. Depending on types of cells where glycolysis occurs,
glycolysis is regulated at several rate-limiting steps such as
glucose uptake, glucose phosphorylation, and/or conversion
of fructose-6-phosphate (F6P) into fructose-1,6-bisphosphate
(F1,6P2). As such, glucose transporter-4 (GLUT4), glucoki-
nase (GK), and 6-phosphofructo-1-kinase (6PFK1) are of
essential importance in the regulation of rates of glycolysis.
Because 6PFK1 is activated by fructose-2,6-bisphosphate
(F2,6P2), the most powerful activator of 6PFK1, F2,6P2
generation is also considered as a regulatory step of glycolysis.
A single enzyme, namely 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (6PFK2/FBPase2), is responsible for both
the production and breakdown of F2,6P2 in a nutritional
status-dependent manner in various cells in particular hepa-
tocytes and pancreatic islet b cells1. Thus, 6PFK2/FBPase2
activities tightly control rates of glycolysis (Fig. 1).
Although glycolysis is viewed as the simplest and most well-
known pathway of nutrient metabolism, much evidence has
increasingly demonstrated the importance of glycolysis in a wide
variety of biological functions from the perspective of integrative
physiology. As is well documented and reviewed elsewhere,
glycolysis is tied closely to functions of glucose production and
insulin secretion in the case of the liver and pancreatic islet b
cells2–7, respectively. Additionally, glycolysis couples glycogen
synthesis in the liver and muscle8 and stimulates lipogenesis in
the adipose through producing the triglyceride backbone, glycerol
phosphate9. In the hypothalamus, glycolysis has a role in glucose-
sensing that leads to termination of meal feeding10–12. With
progresses in research involving interdisciplinary approaches,
glycolysis has recently been shown to alter inﬂammatory
responses9. providing new mechanisms by which glycolysis is
critically involved in integrative regulation of glucose homeostasis.
These aspects are highlighted in the present review. Discussion on
potential therapeutic targets, as well as approaches involving small
molecule activators and/or inhibitors pertinent to diabetes treat-
ment is provided. Glycolysis is also of particular importance in the
control of cancer cell survival. The pertinent information, how-
ever, is not included in this review.
mainly by glucose transporter 2 (GLUT2) or GLUT4. Following
glucose uptake, rates of glycolysis are determined at steps of
glucose phosphorylation, which is catalyzed by hexokinase II or
hexokinase IV (glucokinase, GK), and the generation of fructose-
1,6-bisphosphate, which is catalyzed by 6-phosphofructo-1-kinase
(6PFK1). The latter is activated by fructose-2,6-bisphosphate
(F2,6P2), whose production is controlled by 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (6PFK2/FBPase2). DHAP,
dihydroxyacetone phosphate; TCA, tricarboxylic acid cycle.2. Glycolysis in hepatocytes: coordinated regulation of hepatic
glucose production
2.1. Glycolysis and the control of hepatic glucose production
The liver plays a central role in the maintenance of glucose
homeostasis2,13–16. This role is manifested by the ability of theliver to tightly control hepatic glucose production (HGP). During
fasting, HGP is elevated, making the liver a main source of
glucose production17 (Fig. 2). After feeding, HGP is suppressed
and the liver utilizes and stores glucose (Fig. 2). Using isotopic
techniques and nuclear magnetic resonance (NMR) spectroscopy,
in vivo HGP has been extensively studied3,18,19. Generally,
gluconeogenesis and glycogenolysis are pathways producing
glucose18–23, whereas glycolysis and glycogenesis are pathways
utilizing and storing glucose, respectively. In a given condition,
HGP is the sum of these pathways. While controversy exists on
the fractional contributions of glycogenolysis and gluconeogenesis
to HGP18–23, glucose out of or into the liver is determined by the
ﬂuxes through glycolysis and glycogenesis countering glycogen-
olysis. In fact, enhancement of glycolysis has shown promising
results in lowering the level of plasma glucose14,24. This is strong
evidence to support the idea that glycolysis plays an important
role in the regulation of HGP. In addition, the ﬂux through
6PFK1 may contribute to glycogenesis through the indirect
Figure 2 Glycolysis in the control of hepatic glucose production.
(A) During fasting, rates of glycolysis in the liver are decreased,
which are accompanied by a decrease in rates of glycogenesis and
increases in rates of gluconeogenesis and glycogenolysis. The net
outcome of these pathways leads to an increase in hepatic glucose
production (HGP). (B) In response to feeding, rates of glycolysis are
increased, which are accompanied by an increase in rates of
glycogenesis and decreases in rates of gluconeogenesis and glyco-
genolysis. The net outcome of these pathways leads to suppression of
HGP. Of importance, increased glycolytic pathway provides sub-
strates that facilitate an increase in glycogenesis through both direct
and indirect pathways. Additionally, fructose-2,6-bisphosphate
(F2,6P2), whose levels are increased in response to feeding, not only
enhances rates of glycolysis, but also inhibits rates of gluconeogen-
esis, thereby providing the coordinated regulation of HGP.
Figure 3 Nutritional and hormonal regulation of 6-phospho-
fructo-2-kinase/fructose-2,6-bisphosphatase. Nutritional and hor-
monal regulation of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (6PFK2/FBPase2) is best exempliﬁed by the
responses of liver 6PFK2/FBPase to fasting and/or feeding.
During fasting, glucagon, at increased levels, activates G pro-
tein-coupled receptor signaling cascades to increase protein kinase
A (PKA) activity. The latter brings about the phosphorylation of
Serine-32 of 6PFK2/FBPase2, thereby decreasing the kinase
activity of 6PFK2/FBPase2 and increasing the phosphatase
activity of 6PFK2/FBPase2. As a result, the levels of fructose-
2,6-bisphosphate (F2,6P2) are decreased, leading to reduction of
6-phosphofructo-1-kinase (6PFK1) activity and elevation of fruc-
tose-1,6-bisphosphatase (FBPase) activity. This underlies a
decrease in rates of glycolysis and an increase in gluconeogenesis.
In response to feeding, the levels of glucose are increased, which
Xin Guo et al.360pathway, which is evident by the synthesis of 13C6-labeled
glycogen in the liver after 13C1-labeled glucose infusion8.
13C1-labeled glucose is converted to three carbon carbohydrates,
which then can be converted back to 13C6-glucose-6-phosphate
through gluconeogenic pathway or, strictly, glucose-6-phosphate-
genic pathway, and thereby synthesize 13C6-glycogen.
are accompanied by an increase in the levels of insulin due to
increased glucose-stimulated insulin release (GSIR). Glucose
signaling activates protein phosphatase 2A. Additionally, insulin
signaling activates other protein phosphatase(s). Through an
additive or synergistic manner, glucose and insulin lead to de-
phosphorylation (Serine32) of 6PFK2/FBPase2, thereby increas-
ing the kinase activity of 6PFK2/FBPase2 and decreasing the
phosphatase activity of 6PFK2/FBPase2. As a result, the levels of
F2,6P2 are increased, leading to elevation of 6-phosphofructo-1-
kinase (6PFK1) activity and reduction of FBPase activity. This
underlies an increase in rates of glycolysis and a decrease in rates
of gluconeogenesis.2.2. GK-6PFK2/FBPase2 interaction for coordinated
regulation of glycolysis
In hepatocytes, key rate-determining steps of glycolysis occur
at glucose phosphorylation and generation of F1,6P2 from
F6P. These two steps are catalyzed by GK and 6PFK1,
respectively. Due to the powerful effect of F2,6P2 on activa-
tion of 6PFK1, increasing F2,6P2 concentrations is also
considered a key step to increase glycolysis1,25. 6PFK2/
FBPase2, as the single enzyme that makes F2,6P2 during
feeding and breaks F2,6P2 during fasting, is thus viewed as an
essential regulatory enzyme of glycolysis (Fig. 3). Physiologi-
cally, the amount and activity of either GK or 6PFK2/
FBPase2 are altered by nutritional and hormonal signals in
response to fasting and/or feeding, thereby determining rates
of glycolysis. Given that glucose-6-phosphate is a powerful
activator of glycogen synthase and that F2,6P2, at elevated
levels, is a strong inhibitor of gluconeogenic enzyme fructose-
1,6-bisphosphatase, altering GK or 6PFK2/FBPase2 amount
and/or activity also generates secondary effects on rates of
glycogenesis and gluconeogenesis8,16,26.
As the two key signals that are associated with feeding,
insulin and glucose are well documented to stimulate glyco-
lysis. Mechanistically, insulin and glucose act additively or
synergistically to stimulate hepatocyte glucokinase dissociation
from the inhibitory glucokinase regulatory protein (GKRP)
and/or glucokinase translocation from nucleus to cytosol,
to increase hepatic expression of GK and 6PFK2/FBPase2,
and to maintain the dephosphorylation state of6PFK2/FBPase225,27. Following the ﬁnding that GK can bind
6PFK2/FBPase228, a new paradigm of glycolysis has proposed.
In an acute phase, 6PFK2/FBPase2 promotes GK transloca-
tion, which in turn activates GK27. Meanwhile, 6PFK2/
FBPase2 interacts with GK to form GK:6PFK2/FBPase2
complex, in which GK activity and the kinase activity of
6PFK2/FBPase2 are increased concomitantly29. These aspects
serve as the ﬁrst layer of GK-6PFK2/FBPase2 interaction in
stimulating glycolysis at both the glucose phosphorylation and
F1,6P2 generation steps in a coordinated manner. When the
time of feeding is long enough to alter gene expression or in a
chronic phase, kinase activity-dominant 6PFK2/FBPase2 sti-
mulates hepatic GK expression30,31. This aspect serves as the
second layer of GK-6PFK2/FBPase2 interaction in stimulating
glycolysis at two individual rate-determining steps. Apparently,
this coordinated regulation better explains how hepatocytes
react to the elevated levels of glucose to quickly or maximally
increase glycolysis.
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Both metabolic and regulatory enzymes regulate HGP by
responding to nutritional and hormonal signals. As such,
dysregulation of HGP, referring to failure of insulin to
suppress HGP or even excessive HGP, can be attributed to
direct defects in the enzymes or impairment of the enzymes to
integrate nutritional and hormonal signals. The signiﬁcance of
glycolysis in dysregulated HGP is highlighted by genetic
mutations in GK, which cause maturity-onset diabetes of the
young (MODY) 32,33. Similar effects are seen in the liver-
speciﬁc GK knockout mice, showing an elevated HGP and
hyperglycemia34. In addition to genetic defects in metabolic
enzymes, obesity-associated insulin resistance is accompanied
by impairment in the ability of insulin to increase in vivo GK
activity35. Given these observations, decreased glucose phos-
phorylation as the ﬁrst step of glycolysis critically contributes
to elevated HGP and brings about hyperglycemia.
As mentioned above, HGP is the sum of the four major
glucose metabolic pathways. In diabetes where excessive HGP
is manifest, decreased or relatively decreased activities of
enzymes of glycolysis and glycogenesis, as well as increased
activities of enzymes of glycogenolysis and gluconeogenesis
are seen and usually occur simultaneously. Considering this, it
is necessary to evaluate the role of glycolysis in the dysregula-
tion of HGP relative to the changes in the three other
pathways. For instance, streptozotocin (STZ)-induced mouse
model of type 1 diabetes manifests dramatic decreases in the
amount of hepatic GK and the content of F2,6P2, as well as a
signiﬁcant increase in the amount of hepatic glucose-6-phos-
phatase (G6Pase)30. In contrast, glycolysis may remain
unchanged or even slightly increased due to hyperinsulinemia
in the insulin resistant state24. However, the increase in
glycolysis appears to not be able to counter the dramatic
elevations in glycogenolysis and gluconeogenesis.3. Glycolysis in pancreatic islet b cells: GK as a glucose sensor
The physiological relevance of glycolysis in pancreatic b cells
has been extensively studied and highlighted by the role of GK
in glucose-stimulated insulin secretion (GSIS). In response to
feeding, both the amount and activity of GK are increased.
This in turn enhances glycolysis primarily at the step of
glucose phosphorylation. Because GK activity is positively
correlated with glucose concentrations and consequent insulin
secretion in b cells36–38, GK is thus considered as a glucose
sensor. Following glucose phosphorylation, the next rate-
determining step of glycolysis is the generation of F1,6P2
from F6P. For the same reasons described for hepatocytes,
6PFK2/FBPase2 is another enzyme that critically determines
rates of glycolysis. As such, both GK and 6PFK2/FBPase2
tightly control GSIS in response to feeding or an elevation of
plasma levels of glucose. Following the identiﬁcation of GK-
6PFK2/FBPase2 interactions in b cells, the signiﬁcance of
6PFK2/FBPase2 in b cell physiology has since been re-
evaluated. The GK-6PFK2/FBPase2 interaction was, in fact,
identiﬁed initially in b cells, and then extended to hepato-
cytes28,29,39. In terms of enhancing glycolysis, the formation of
GK:6PFK2/FBPase2 complex favorably increases activities of
both GK and 6PFK2/FBPase2. As such, glycolysis is
enhanced at two rate-determining steps simultaneously,resulting in a maximal increase in glycolysis. The latter clearly
meets the physiological need of feeding: to quickly increase
insulin secretion so that circulating glucose returns to levels
within a narrow physiological range in a short time period.
Genetic defects in GK leads to MODY32,33. This argues in
favor of the importance of GK and glycolysis in the control of
glycemia. On the one hand, decreased glycolysis in hepatocytes
contributes to excessive HGP as discussed in the previous
section. On the other hand, decreased glycolysis in pancreatic
b cells accounts for hypoinsulinemia or defects in GSIS. These
two events, in combination, demonstrate that decreased
glycolysis is the cause of hyperglycemia in MODY patients.
In contrast, certain GK mutants are associated with increased
GK activity, thereby contributing to familial hyperinsulinemic
hypoglycemia40. While decreased glycolysis in hepatocytes and
b cells may equally contribute to hyperglycemia in MODY, a
decrease or a relative decrease in glycolysis in hepatocytes may
be more important than a decrease in b cells in type 2 diabetes.
This is because most type 2 diabetes patients have hyperinsu-
linemia. In other words, the inability of insulin to suppress
HGP likely makes a greater contribution to hyperglycemia in
type 2 diabetes. In this situation, increases in hepatic gluco-
neogenesis and glycogenolysis also contribute to hyperglyce-
mia. At this point, it is unknown if genetic defects exist in
6PFK2/FBPase2, and the defects, if they exist, contribute to
dysfunction in GSIS and to hyperglycemia.4. Glycolysis in adipocytes: integrative regulation of metabolic
and inﬂammatory responses
4.1. Glycolysis and white adipose tissue physiology
White adipose tissue is an important metabolic organ, which
stores energy when energy is in excess and releases energy
when energy is required. In the process of storing energy, free
fatty acids are generated as the products of triglyceride
hydrolysis during delivery of both dietary fats in the form of
chylomicrons and endogenous fats in the form of very low
density lipoproteins in response to feeding. Free fatty acids
and glycerol, products of triglyceride hydrolysis, are then
transported into adipocytes via a transport complex. Inside
adipocytes, free fatty acids are re-esteriﬁed and the resultant
triglycerides are stored in lipid droplets. However, inside
adipocytes, circulation-derived glycerol needs to be activated
by phosphorylation, which requires glycerol kinase (GyK).
Although a role for GyK has been previously postulated41,
other pathways for the generation of glycerol-3-phosphate
exist and appear to play a greater role in addition to
glyceroneogenesis42,43, glycolysis in adipocytes serves a critical
way to generate glycerol-3-phosphate. In fact, glucose uptake
following insulin-stimulated GLUT4 translocation provides
sufﬁcient substrate that can be metabolized through glycolysis
to produce glycerol-3-phosphate. Moreover, adipocyte glyco-
lysis also generates pyruvate whose further metabolism in
mitochondria provides acetyl-CoA. The latter is used for
generation free fatty acid synthesis through lipogenesis, and
then to triglycerides. In adipocytes, hexokinase catalyzes
glucose phosphorylation. This step, however, is not a rate-
limiting step. Instead, generation of F1,6P2 from F6P is the
rate-limiting step. Similar to that in hepatocytes and b cells,
F2,6P2 also activates 6PFK1 to enhance glycolysis in
Xin Guo et al.362adipocytes. However, inducible 6-phosphofructo-2-kinase/fruc-
tose-2,6-bisphosphatase (iPFK2), encoded by PFKFB39,44, is the
enzyme that generates F2,6P2 Given this, glycolysis is key to
storing energy in adipocytes. In support of this, iPFK2 is
necessary for an increase in fat storage in white adipose tissue
and in fat deposition in adipocytes induced by peroxisome
proliferator-activated receptor g (PPARg) activation45.
Adipose tissue is also an endocrine organ, whose endocrine
functions tightly control systemic metabolic homeostasis. In
fact, the balance between the release of pro-hyperglycemic
factors such as free fatty acids and resistin and anti-hypergly-
cemic factors such as adiponectin, as well as the production of
proinﬂammatory cytokines such as tumor necrosis factor
alpha (TNFa) and interleukin 6 (IL-6) from both adipocytes
and adipose tissue macrophages and other immune cells,
determine insulin sensitivity and glucose metabolism locally
in adipose tissue and distally in liver and skeletal muscle46–49.
Of signiﬁcance, the endocrine function of adipose tissue is tied
closely with adipocyte glucose and lipid metabolism, which is
detailed in the following sections.4.2. Integrative regulation of adipocyte metabolic and
inﬂammatory responses
The pathophysiological relevance of iPFK2 to diabetes is
evidenced by the fact that the expression of iPFK2 in adipose
tissue is decreased in db/db mice and PPARg2-disrupted
mice44,45, which all exhibit insulin resistance50–53. Under
physiological conditions, iPFK2 stimulates adipocyte glycoly-
sis44. The resultant increase in glycolysis not only provides
lactate and pyruvate (which are converted into acetyl-CoA
and used for lipogenesis to provide free fatty acids), but also
increases the production of dihydroxyacetone phosphate,
which is converted into glycerol-3-phosphate as a required
substrate for adipocyte triglyceride synthesis. This role of
iPFK2 is supported by the fact that knockdown of iPFK2 in
adipocytes leads to a decrease in the incorporation of glucose
into lipid. Of importance, the impairment in using glucose as a
fuel due to iPFK2 disruption causes a compensatory increase
in fatty acid oxidation. The latter contributes to decreased fat
accumulation, but more importantly, triggers oxidative stress
and increases the adipocyte inﬂammatory response9. Of sig-
niﬁcance, inhibition of fatty acid oxidation by etomoxir brings
about a decrease in the production of reactive oxygen species
(ROS) in iPFK2-knockdown adipocytes. As further
evidence, overexpression of iPFK2 in adipocytes enhances
glycolysis and glycolysis-driven lipogenesis, which are accom-
panied by decreases in adipocyte inﬂammatory signaling
through the nuclear factor kappa B (NF-kB) pathway and
in adipocyte expression of proinﬂammatory cytokines54.
Clearly, iPFK2 serves as a coordinator that links adipocyte
glycolysis, glycolysis-driven lipogenesis, and the inﬂammatory
response.
The role of iPFK2 in integrative regulation of adipocyte
metabolic and inﬂammatory responses is also highlighted by
the fact that iPFK2 is involved in the anti-inﬂammatory and
anti-diabetic effect of PPARg activation (i.e., treatment with
rosiglitazone). In support of this, treatment with rosiglitazone
restores euglycemia and reverses high fat diet-induced insulin
resistance and glucose intolerance in wild-type mice, but not in
iPFK2-disrupted mice45. These in vivo results are recapitulatedin cultured 3T3-L1 adipocytes. Furthermore, inhibiting exces-
sive fatty acid oxidation in iPFK2-knockdown adipocytes
rescues the effects of PPARg activation on suppressing
inﬂammatory signaling and proinﬂammatory cytokine expres-
sion and on improving adipocyte insulin signaling45.5. Glycolysis in hypothalamic neurons: glucose-sensing for
appetite regulation
Numerous studies have demonstrated the importance of food
intake in the control of metabolic homeostasis. As it is well
accepted, food intake is controlled by the central nervous
system where the hypothalamus plays the most important role.
In the hypothalamus, certain neurons express orexic neuropep-
tide Y (NPY) and agouti-related protein (AgRP), both of which
increase food intake. In contrast, certain neurons express
anorexic pro-opiomelanocortin (POMC) and cocaine-ampheta-
mine-related transcript (CART), both of which suppress food
intake55–59. While investigating how nutrients are sensed by
hypothalamic neurons, a number of studies have demonstrated
that AMP-activated protein kinase (AMPK) is a key cellular
energy sensor that responds to peripheral signals, e.g., glucose
and leptin, to direct food intake60–66. For example, decreased
hypothalamic AMPK signaling appears to be responsible for
the anorexic effects caused by re-feeding and leptin61,67,68. On
the other hand, activating hypothalamic AMPK signaling has
been shown to abolish the anorexic effect induced by leptin67.
In the hypothalamus, mammalian target of rapamycin (mTOR)
appears to be another cellular sensor involved in nutrient
sensing, and likely mediates anorexic effects caused by re-
feeding and leptin. In contrast, decreasing mTOR signaling
abolishes the anorexic effect of leptin. As such, hypothalamic
mTOR plays a key role in the control of food intake with or
independent of AMPK.
A role for glucose sensing in the regulation of food intake
was initially proposed as glucostatic hypothesis 60 years
ago69–71. This hypothesis was all but abandoned, but has been
recently revisited and revised72. New evidence now points to
an essential role for glucose metabolism, not the levels of
glucose, in the regulation of food intake72, although a direct
link between neuronal glucose sensing and the physiological
regulation of food intake has yet to be established73. In
cultured hypothalamic neurons, glycolysis mediates the effect
of glucose on suppressing AgRP expression74. This effect,
however, appears to be independent of AMPK, although
glucose decreases AMPK phosphorylation. While addressing
molecular mechanisms underlying glucose sensing, much
attention has been paid to the role of GK in the control of
neuronal glucose metabolism. In fact, GK in hypothalamic
neurons has been proposed as a glucosensor, paralleling GK
function in pancreatic b cells and is key to the regulation of
food intake10–12,75–78. As a key regulatory enzyme of glyco-
lysis, 6PFK2/FBPase2 is present in the brain79. However,
6PFK2/FBPase2 has not yet been functionally characterized
in neurons of the hypothalamus.
The pathophysiological signiﬁcance of glucose sensing in
glucose homeostasis is evidenced by the fact that disruption of
glucose sensing in POMC neurons in mice leads to impairment
of whole-body response to a systemic glucose load80. Addition-
ally, glucose sensing in POMC neurons is defective in
diet-induced obesity, demonstrating a role for loss of glucose
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diabetes.6. Anaerobic glycolysis
Anaerobic glycolysis occurs in the absence of oxygen, e.g., in
muscle cells during vigorous physical activity, and terminates
in the formation of lactate. Of importance, lactate generated in
muscle cells circulates to the liver, where lactate is converted
back to glucose. In general, anaerobic glycolysis functions to
help muscles burn fuels, which is different than aerobic
glycolysis. The latter is involved in many biological functions
in a wide verity of tissue/cells as discussed above. Anaerobic
glycolysis also occurs in erythrocytes, which lack enzymes of
the tricarboxylic acid cycle, and in other cells or tissues
including brain, gastrointestinal tract, renal medulla, adipose
tissue, and skin. Unlike aerobic glycolysis, relatively little is
known about changes in anaerobic glycolysis in diabetes.
Previous evidence supports the notion that elevated plasma
levels of lactate are an independent risk factor for the
development of type 2 diabetes81. Additionally, lactate- and
pyruvate-interconversion rates are greatly enhanced in
patients of type 2 diabetes, likely due to concomitant impair-
ment in the oxidative pathway of glucose metabolism82.
Although anaerobic glycolysis appears to be increased during
diabetes, lactate, the end product of anaerobic glycolysis,
per se, does not induce insulin resistance83. Given this,
anaerobic glycolysis likely has a limited role in the pathogen-
esis of diabetes. However, during the development of diabetes
complications, ischemia is common and considered as a key
factor triggering anaerobic glycolysis through mechanisms
involving hypoxia-inducible factor 1 (HIF1). The latter sti-
mulates anaerobic glycolysis84, which may be a defensive
response that is involved in protection against cell/tissue
injury. Hypoxia also occurs in adipose tissue during obesity.
As such, HIF1 is likely a regulator of chronic inﬂammation in
adipose tissue85,86. To date, the exact role for anaerobic
glycolysis in regulating adipose tissue inﬂammation has not
been elucidated.Figure 4 Glycolysis in major tissues in relation to diabetes (A) In
type 1 diabetes, insulin insufﬁciency leads to a decrease in rates of
glycolysis in key tissues involved in the regulation of systemic
glucose homeostasis. (B) In type 2 diabetes, hyperinsulinemia
brings about a compensatory increase in rates of glycolysis in the
liver, adipose tissue, and pancreatic b cells. Unlike other tissues,
the brain exhibits a decrease in rates of glycolysis as evidenced in
rodent models of obesity and type 2 diabetes.7. Targeting glycolysis for diabetes treatment
7.1. Mechanisms of actions for potential targets in glycolysis
As discussed above, glycolysis critically regulates physiological
functions of a number of tissues/organs that are essential for
glucose metabolic homeostasis in a cell-type-dependent man-
ner. Among those functions, glucose production from hepa-
tocytes/liver and insulin secretion in pancreatic b cells have
attracted much attention. Over the past several decades, a few
in vivo studies have validated reduction of HGP as a potential
treatment for diabetes87–89. Similarly, increasing insulin secre-
tion from pancreatic b cells is repeatedly shown as a powerful
way to restore euglycemia90. To be noted, reduction of HGP is
indeed a critical consequence secondary to increased insulin
secretion. From this perspective, mechanisms of actions
(MOA) of glycolysis-based insulin secretagogues, as well as
all other insulin-secretagogues, should not be limited to insulin
secretion, and should, at least, include suppression of HGP.
Similarly, restoring euglycemia upon suppression of HGPlowers hyperinsulinemia due to a decrease in GSIS. In
combination, a decrease in levels of glucose and/or insulin
has the potential to also bring about a secondary increase in
fatty acid oxidation in skeletal muscle, thereby contributing to
improvement of overall systemic metabolic homeostasis15.
Further interpretations pertinent to MOA are detailed in the
following sections based on speciﬁc targets. Overall, changes
in rates of glycolysis in key tissues/cells involved in the control
of systemic glucose homeostasis serve as the rationale of
targeting glycolysis for treatment of diabetes (Fig. 4).
7.2. Major targets
7.2.1. GK
GK is abundantly expressed in both hepatocytes and pan-
creatic b cells. Thus, GK activation is expected to increase
glycolysis in hepatocytes and b cells, leading to reduction of
HGP and increased insulin secretion, respectively. At the
cellular level, 6PFK2/FBPase2 acts as an endogenous activa-
tor and GKRP acts as an endogenous inhibitor of GK,
thereby critically regulating glucose phosphorylation in both
hepatocytes and pancreatic b cells. The potency of GK in
terms of reducing HGP has been validated by a few in vivo
studies via adenoviral overexpression of GK91,92. Interestingly,
a GK activator has been developed and characterized based
on its role in stimulating insulin secretion in pancreatic b cells.
The activator likely inhibits the binding of GKRP to GK90.
Following lead optimization, potent preclinical compounds
were advanced through phase 2 trials. However, the GK
activator project was eventually discontinued93. Safety con-
cerns associated with the MOA of these compounds may
diminish the ability of targeting GK.
7.2.2. 6PFK1
6PFK1 catalyzes the generation of F1,6P2 from F6P as
another rate-determining step of glycolysis, and is thus
considered as a potential target for glycolysis-based treatment
of diabetes. Among known activators, F2,6P2 is the most
powerful activator of 6PFK1. For this reason, 6PFK2/
FBP2ase, which both makes and breaks down F2,6P2, is also
a potential target for glycolysis-based treatment of diabetes,
and is ranked at a higher priority than 6PFK1 as a potential
target for treatment of diabetes.
Xin Guo et al.3647.2.3. 6PFK2/FBPase2
6PFK2/FBPase2 has been validated as an interesting target
for reduction of HGP in mice. Overexpression of a kinase
dominant/bisphosphatase-deﬁcient 6PFK2/FBPase2 is shown
to increase hepatic content of F2,6P2, which lowers levels of
plasma glucose in both type 1 and type 2 diabetic mouse
models14,24. Of importance, hepatic 6PFK2/FBPase2 over-
expression shows the same effects as seen with hepatic GK
overexpression through activation of glycolysis, but does not
cause fatty liver. The underlying mechanisms for the metabolic
differences are due to the ability of the overexpressed 6PFK2/
FBP2ase to induce GK expression at a level sufﬁcient to
initiate glycolysis but not in excess, which would promote
lipogenesis94. To be noted, 6PFK2/FBP2ase and F2,6P2 serve
as therapeutic targets not only through activation of 6PFK195,
but also through modiﬁcation of expression of genes for
metabolic enzymes30. Since F2,6P2 itself is controlled by the
relative activities of the kinase and bisphosphatase domains of
6PFK2/FBP2ase, an activator of 6PFK2 and/or an inhibitor
of FBPase2 would be efﬁcacious for reduction of HGP by
increasing F2,6P2 content in the liver. As an anti-diabetic
reagent, vanadate is shown to increase 6PFK2/FBP2ase.
However, vanadate also has broader effects on other enzymes
that are not metabolic and/or regulatory enzymes of glyco-
lysis96. Identifying new small molecule activators of 6PFK2/
FBP2ase is ongoing, but may be challenging.
7.2.4. Inducible 6PFK2 (iPFK2)
On the one hand, PPARg agonists activate iPFK2. On the
other hand, iPFK2 is involved in the anti-diabetic effect of
rosiglitazone, one of the two prescribed PPARg agonists that
are powerful anti-diabetes medicines. Due to safety concerns,
rosiglitazone has been withdrawn from European markets and
pioglitazone use has been suspended in Europe. Compared
with PPARg activation that has broader effects on many
biological events, the overall effects of iPFK2 activation are
expected to be limited mainly to metabolism in limited number
of cell types. If true, iPFK2 activation may have fewer off
target effects. To date, small molecular activators of iPFK2
are not available.
7.3. Additional targets and potential approaches
In terms of enhancing glycolysis, a strategy that coordinately
affects several targets would provide more pronounced effects.
A single effector may accomplish this by either directly inter-
acting with or indirectly modifying metabolic and regulatory
enzymes. Unlike activator(s) or inhibitor(s) of metabolic and/or
regulatory enzymes of glycolysis, other unclassiﬁed approaches
may also work through indirect effects to enhance glycolysis.
For example, metformin is an anti-diabetic medicine that has
been widely used for many decades. While the exact MOA of
metformin are not clear, metformin treatment has been repeat-
edly shown to enhance liver glycolysis, likely through mechan-
isms involving AMPK activation97,98. Berberine is also a
powerful anti-diabetic compound that may also act through
mechanisms involving AMPK activation to enhance glycoly-
sis99,100. However, these compounds have broader effects, and
cannot be simply considered as glycolysis-based approaches.
Epigenetic regulation of metabolic and regulatory enzymes
of glycolysis is a new ﬁeld, which is currently beingexplored101. Identifying and characterizing new regulator(s)
that stimulate the expression of key enzymes, such as GK,
6PFK1, and 6PFK2/FBPase2, could provide new targets and/
or novel approaches for the treatment of diabetes.8. Conclusions
Glycolysis is of particular importance in the regulation of
systemic glucose homeostasis. This review has discussed how
glycolysis is regulated in a cell-type-dependent manner, and
summarized key glycolysis metabolic and regulatory enzymes
that are potential targets for treatment of diabetes. The
pertinent mechanisms of actions have also been discussed.
While many targets are promising, there still will be a long
way to go to develop glycolysis-based therapeutic(s) that are
effective enough to restore euglycemia, and more importantly
also safe enough to not cause side effects. In future studies, it
would be equally important to also ﬁnd a better way to deliver
an effector, which would maintain the same efﬁcacy at a
lower dose.Acknowledgements
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